UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

被引：0
作者：
N Santos
R Rodríguez-Romanos
J B Nieto
I Buño
C Vallejo
A Jiménez-Velasco
S Brunet
E Buces
J López-Jiménez
M González
C Ferrá
A Sampol
R de la Cámara
C Martínez
D Gallardo
机构：
[1] Institut Català d’Oncologia,Clinical Hematology Department
[2] IDIBGi,Hematology Department
[3] Hospital Morales Meseguer,Hematology Department
[4] Hospital Gregorio Marañón,Hematology Department
[5] Hospital Universitario Central de Asturias,Hematology Department
[6] Hospital Carlos Haya,Hematology Department
[7] Hospital de la Santa Creu i Sant Pau,Hematology Department
[8] Hospital Ramón y Cajal,Hematology Department
[9] Hospital Universitario,Hematology Department
[10] Institut Català d’Oncologia,Hematology Department
[11] Hospital Son Espases,Hematology Department
[12] Palma de Mallorca,undefined
[13] Hospital La Princesa,undefined
[14] Hospital Clínic,undefined
来源：
Bone Marrow Transplantation | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Minor histocompatibility Ags (mHags) have been implicated in the pathogenesis of GVHD after allogeneic hematopoietic stem cell transplantation (HSCT). Uridine diphospho-glucuronosyltransferase 2B17 (UGT2B17) gene deletion may act as a mHag and its association with acute GVHD (aGVHD) has been described. We retrospectively studied the clinical impact of a UGT2B17 mismatch in a cohort of 1127 patients receiving a HSCT from an HLA-identical sibling donor. UGT2B17 mismatch was present in 69 cases (6.1%). Incidence of severe aGVHD was higher in the UGT2B17 mismatched pairs (22.7% vs 14.6%), but this difference was not statistically significant (P: 0.098). We did not detect differences in chronic GVHD, overall survival, relapse-free survival, transplant-related mortality or relapse. Nevertheless, when we analyzed only those patients receiving grafts from a male donor (616 cases), aGVHD was significantly higher in the UGT2B17 mismatched group (25.1% vs 12.8%; P: 0.005) and this association was confirmed by the multivariate analysis (P: 0.043; hazard ratio: 2.16, 95% confidence interval: 1.03–4.57). Overall survival was worse for patients mismatched for UGT2B17 (P: 0.005). We conclude that UGT2B17 mismatch has a negative clinical impact in allogeneic HSCT from HLA-identical sibling donors only when a male donor is used. These results should be confirmed by other studies.
引用
收藏
页码：79 / 82
页数：3
相关论文
共 85 条
[1]  
Beaulieu M(1997)Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme DNA Cell Biol 16 1143-1154
[2]  
Levesque E(1999)Characterization of UDP-glucuronosyltransferases active on steroid hormones J Steroid Biochem Molec Biol 69 413-423
[3]  
Tchernof A(2010)Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity Drug Metab Dispos 38 2204-2209
[4]  
Beatty BG(2004)Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15 Genomics 84 707-714
[5]  
Belanger A(2008)Adaptive evolution of UGT2B17 copy-number variation Am J Hum Genet 83 337-346
[6]  
Hum DW(2006)Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism J Clin Endocr Metab 91 687-693
[7]  
Hum DW(2003)A human minor histocompatibility antigen resulting from differential expression due to a gene deletion J Exp Med 197 1279-1289
[8]  
Belanger A(2007)A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403 Transplantation 83 1242-1248
[9]  
Levesque E(2005)A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation Br J Haematol 129 221-228
[10]  
Barbier O(2009)Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease Nat Genet 41 1341-1344
123456789